Abstracts tagged "ACPA"

Abstract Number: 2919 • 2017 ACR/ARHP Annual Meeting
Number and Type of ACPA Fine Specificities Are Correlated to High Resolution Computed Tomography Parenchymal Lungs Changes in Patients with Early Untreated Rheumatoid Arthritis
Vijay Joshua¹, Aase Hensvold¹, Gudrun Reynisdottir¹, Monika Hansson¹, Guy Serre², Johan Grunewald³, Katerina Chatzidionysiou¹ and Anca I. Catrina¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM, Toulouse, France, ³Division of Respiratory Medicine, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Airways abnormalities that are consistent with inflammation are common in anti-CCP2 positive subjects without inflammatory arthritis. Anti-CCP2 antibodies are associated with HRCT parenchymal lung…
Abstract Number: 836 • 2017 ACR/ARHP Annual Meeting
B Cell Receptor Sequencing of Anti-Citrullinated Protein Antibody Expressing B Cells Indicates a Selective Advantage for the Introduction of N-Glycosylation Sites during Somatic Hypermutation
Rochelle D. Vergroesen¹, Linda Slot¹, Lise Hafkenscheid¹, Marvyn T. Koning², Ellen I.H. van der Voort³, Christine A. Grooff¹, George Zervakis², Tom W.J. Huizinga¹, Theo Rispens⁴, Hendrik Veelken², Rene E.M. Toes¹ and Hans U. Scherer³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Hematology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Immunopathology, Sanquin Research, Amsterdam, Netherlands
Background/Purpose: The vast majority (>90%) of anti-citrullinated protein antibodies (ACPA) of the IgG isotype in serum and synovial fluid of patients with rheumatoid arthritis carry…
Abstract Number: 970 • 2017 ACR/ARHP Annual Meeting
ACPA Activate Challenged Synovial Fibroblasts through a PAD Dependent Mechanism: A Potential Explanation of the “Second Hit Model” in RA
Meng Sun¹, Vijay Joshua¹, Akilan Krishnamurthy¹, Aase Hensvold¹, Yanying Liu², Sergiu-Bogdan Catrina³, Caroline Ospelt⁴, Vivianne Malmström¹, Johanna Steen¹, Marianne Engström¹, Heidi Wähämaa¹, Bence Rethi¹ and Anca I. Catrina¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Peking University People's Hospital, Beijing, China, ³Molecular Medicine and Surgery, Molecular Medicine and Surgery, Stockholm, Sweden, ⁴Center of Experimental Rheumatology, University Hospital Zürich, Zurich, Switzerland
Background/Purpose: Anti-citrullinated proteins antibodies (ACPAs) injected in mice induce IL-8 dependent bone loss and arthralgia, but no synovial changes. We hypothesized that additional stimulus, sensitizing…
Abstract Number: 990 • 2017 ACR/ARHP Annual Meeting
Higher Omega-6 to Omega-3 Fatty Acid Ratio Is Associated with Increased Odds of Inflammatory Arthritis in a Health Fair Population Positive for Anti-Citrullinated Protein Antibodies (ACPA)
Kristen J. Polinski¹, Ryan W. Gan², Elizabeth A. Bemis¹, M. Kristen Demoruelle³, Michael J. Clare-Salzler⁴, V. Michael Holers⁵, Kevin D. Deane⁶ and Jill M. Norris⁷, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Colorado School of Public Health, University of Colorado Denver, Aurora, CO, ³1775 Aurora Ct, 1775 Aurora Ct, Aurora, CO, ⁴Experimental Pathology, University of Florida, College of Medicine, Gainesville, FL, ⁵Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁷Department of Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: We previously found that lower levels of omega-3 fatty acids (n-3 FA) were associated with the presence of inflammatory arthritis (IA) as well as…
Abstract Number: 1250 • 2017 ACR/ARHP Annual Meeting
Outcomes in Real-World Patients with Early Aggressive Rheumatoid Arthritis
Keith Knapp^1,2, Eric Mueller^1,2 and Gary Craig^1,2, ¹Arthritis Northwest PLLC., Spokane, WA, ²Discus Analytics LLC., Spokane, WA
Background/Purpose: The window of opportunity to address early rheumatoid arthritis (RA) in patients (pts) is well documented. However early aggressive (agr) RA needs further study…
Abstract Number: 1356 • 2017 ACR/ARHP Annual Meeting
Is ACPA-Positive RA Still a More Severe Disease Than ACPA-Negative RA? a Longitudinal Cohort Study in RA-Patients Treated from 2000 Onwards
Aleid C. Boer¹, Annelies Boonen² and Annette H.M. van der Helm-van Mil³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands, Maastricht, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated-protein antibodies (ACPA)-positive rheumatoid arthritis (RA) is considered as more severe than ACPA-negative RA, because of its association with joint destruction. Clinically relevant joint…
Abstract Number: 65 • 2017 ACR/ARHP Annual Meeting
RA-Associated Antibodies Targeting Post Translational Modification Have Different Osteoclastogenetic Potential
Akilan Krishnamurthy¹, Johanna Steen², Caroline Grönwall³, Gustaf Wigerblad⁴, Camilla Svensson^5,6, Heidi Wähämaa¹, Vivianne Malmström¹, Bence Rethi¹ and Anca I. Catrina¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁵Dept. of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden, ⁶Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Some but not all antibodies against citrullinated modified proteins (ACPA) promote osteoclastogenesis and bone destruction in vitro and in vivo. We aimed to investigate…
Abstract Number: 1376 • 2017 ACR/ARHP Annual Meeting
Diagnostic Performance of 7 Different Anti-Cyclic Citrullinated Peptide Antibody and 6 Rheumatoid Factor Assays in a Primary Diagnostic, Consecutive Rheumatological Population in a Secondary Care Hospital
Lieve Van Hoovels¹, Julie Jacobs¹, Bert Vander Cruyssen², Stefanie Van den Bremt¹, Patrick Verschueren³ and Xavier Bossuyt⁴, ¹Laboratory medicine, OLV Hospital, Aalst, Belgium, ²Rheumatology, OLV hospital, Aalst, Belgium, ³Division of Rheumatology, University Hospital Leuven, Leuven, Belgium, ⁴Laboratory medicine, University Hospital Leuven, Leuven, Belgium
Background/Purpose: The clinical diagnosis of rheumatoid arthritis (RA) remains a challenge, making serological markers most interesting. The 2010 ACR/EULAR classification criteria for RA take into…
Abstract Number: 327 • 2017 ACR/ARHP Annual Meeting
Association of Anti-Cyclic Citrullinated Peptide Seropositivity and Lean Mass Index with Low Bone Mineral Density in Patients with Rheumatoid Arthritis
Katherine D. Wysham¹, Dolores M. Shoback², Kashif Jafri¹, Sarah L. Patterson³, Gabriela Schmajuk⁴, John B. Imboden Jr.⁵ and Patricia P. Katz⁵, ¹University of California, San Francisco, San Francisco, CA, ²Medicine, San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ³Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ⁵Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Osteoporotic fractures are associated with high morbidity and mortality. Persons with rheumatoid arthritis (RA) have twice the risk of osteoporosis-related fracture than age-matched…
Abstract Number: 1383 • 2017 ACR/ARHP Annual Meeting
IMPACT of Smoking in the Expression of Periodontitis and Anticitrullinated Protein Antibodies in Rheumatoid Arthritis
Jerián González Febles¹, Jorge Luis Garnier Rodríguez², Fernando Sánchez-Alonso³, Sagrario Bustabad⁴, Federico Díaz-González⁵, Mariano Sanz Alonso¹ and Beatriz Rodriguez Lozano⁶, ¹Periodontology, Universidad Complutense de Madrid, Madrid, Spain, ²Odontology, Dental Clinic Garnier, S/C Tenerife, Spain, ³Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁴Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ⁵Servicio de Reumatología. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁶Rheumatology, Hospital de Canarias, S/C Tenerife, Spain
Background/Purpose: Environmental, genetic and epigenetic factors can induce citrullination of structural peptides by the enzyme PAD, which induce anti-citrullinated protein antibodies (ACPA) preceding RA. Among…
Abstract Number: 410 • 2017 ACR/ARHP Annual Meeting
Association between Anti-Citrullinated Protein Antibody Status and the Incidence of Erosive Disease in Patients with RA
Leslie R Harrold¹, Heather J. Litman², SE Connolly³, E Alemao³, Sabrina Rebello⁴, W Hua² and Joel Kremer⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, Southborough, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC, Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: RA is characterized by the production of autoantibodies including anti-citrullinated protein antibodies (ACPAs).1 ACPAs are considered a prognostic indicator for more severe RA and…
Abstract Number: 1432 • 2017 ACR/ARHP Annual Meeting
The Prognostic Value of IgA Subtypes of Rheumatoid Factor and Anti-Citrullinated Protein Antibodies (ACPA) for Prediction of Therapeutic Responses to TNF Inhibitory Therapy in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Farideh Alasti², Paul Studenic¹ and Günter Steiner², ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid factor (RF) and Anti-Citrullinated Protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the…
Abstract Number: 413 • 2017 ACR/ARHP Annual Meeting
Economic Burden Associated with Anti-Cyclic Citrullinated Peptide Antibody Positivity in Patients Newly Diagnosed with RA
J An¹, Z Bider², J Kang¹, E Alemao³, SE Connolly³ and TC Cheetham¹, ¹Western University of Health Sciences, Pomona, CA, ²Southern California Permanente Medical Group, Pasadena, CA, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) antibody positivity has been suggested as a strong predictor of joint erosion as well as a potential biomarker for guiding…
Abstract Number: 1454 • 2017 ACR/ARHP Annual Meeting
Association of Poor Prognostic Factors with Medication Persistence Among Adult RA Patients within a Community of Rheumatology Clinics
Damemarie Paul¹, Laura McDonald², Aarti Rao³, Ruthwik Anupindi⁴ and Keith Knapp^5,6, ¹HEOR, Bristol Myers Squibb, Lawrence Township, NJ, ²CORDS, Bristol Myers Squibb, Uxbridge, United Kingdom, ³Analytics, Mu-Sigma, Bengaluru, India, ⁴Analytics, Mu-Sigma, Lawrence Township, NJ, ⁵Arthritis Northwest PLLC., Spokane, WA, ⁶Discus Analytics LLC., Spokane, WA
Background/Purpose: A fixed treatment paradigm often exists for Rheumatoid Arthritis(RA) patient(pts)1. However, RA is a heterogeneous disease and differences in pts’ serostatus affect disease progression.…
Abstract Number: 432 • 2017 ACR/ARHP Annual Meeting
ACPA and RF As Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort
Janet E. Pope¹, Emmanouil Rampakakis², Mohammad Movahedi³, Angela Cesta³, John S. Sampalis⁴ and Claire Bombardier³, ¹Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ²JSS Medical Research, Montreal, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴McGill University, Montreal, QC, Canada
ACPA and RF as Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data From a Rheumatoid Arthritis CohortBackground/Purpose: Positive serology for anti-citrullinated protein antibody…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].